GlassScriptPhysician profile
Dennis Kasimian
NPI 1558326975
$947.02
in general payments reported to CMS, 2019-2025
18 companies · $293 in 2025
The $293 reported for 2025 was more than what 83% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.42 · 2021: $135 · 2022: $94.80 · 2023: $172 · 2024: $236 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $157.20 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Seagen INC. | $115.12 | 2022-2023 | Adcetris |
| Incyte Corporation | $100.97 | 2021-2025 | Monjuvi, Pemazyre, Zynyz |
| Sobi, INC | $94.51 | 2025 | |
| Stemline Therapeutics INC. | $67.64 | 2025 | Orserdu |
| Pharmaessentia USA Corporation | $56.68 | 2024 | Besremi |
| Janssen Biotech, INC. | $47.74 | 2022-2025 | Tecvayli, Talvey |
| Ipsen Biopharmaceuticals, INC | $45.33 | 2021 | |
| Amgen INC. | $37.64 | 2021-2023 | Vectibix, Xgeva, Nplate |
| Karyopharm Therapeutics INC. | $34.13 | 2023 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $33.54 | 2024 | Tagrisso |
| Syndax Pharmaceuticals, INC. | $28.66 | 2025 | |
| Progenics Pharmaceuticals, INC. | $27.89 | 2024 | |
| Blue Earth Diagnostics | $22.83 | 2024 | |
| Merck Sharp & Dohme LLC | $22.28 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $19.83 | 2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $18.61 | 2021 | |
| Siemens Medical Solutions USA, INC. | $16.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Kasimian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.